Non-small cell lung cancer (Homo sapiens)

From WikiPathways

Revision as of 14:37, 19 April 2018 by Egonw (Talk | contribs)
Jump to: navigation, search
ERReduced apoptosisCell cycle progressionProliferationLegendOverexpression of ERBB2?DNA DamageAntiapoptosisActivating mutationCDKN2AEGFCalcium Signaling PathwayCDK4EML4KRASEGFRBAK1PIK3R1PIP3CDKN1ATP53RASSF1RB1IP3DAGFHITTGFACa2+BADRetinoic acidPRKCAPDK1RARBPIK3CASTK4HRASJAK3AKT1ERBB2PPPPGRB2SOS1SOS2KRASNRASARAFBRAFRAF1MAP2K1MAP2K2PPPPMAPK1PPMAPK3PPPLCG1PPPLCG2PRKCBPRKCGPIK3CBPIK3CDAKT2PAKT3CASP9PFOXO3PPPI3K-Akt Signaling PathwayALKSTAT3STAT5APSTAT5BPCell survivalPIK3CAPIK3CBPIK3CDPIK3R2PIK3R3Ras Signaling PathwayCCND1RASSF5Reduced apoptosisRXRARXRBRXRGTumor progressionCDK6CCND1E2F1E2F2E2F3G1 to S progressionp53 Signaling PathwayCell CycleCell CycleBAXDDB2GADD45AGADD45BGADD45GPOLKInactivating mutation


Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.

Source: KEGG

Quality Tags

Ontology Terms



View all...
  1. Connolly RM, Nguyen NK, Sukumar S; ''Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment.''; Clin Cancer Res, 2013 PubMed Europe PMC
  2. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA; ''The biology and treatment of EML4-ALK non-small cell lung cancer.''; Eur J Cancer, 2010 PubMed Europe PMC
  3. Deng WG, Nishizaki M, Fang B, Roth JA, Ji L; ''Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.''; Biochem Biophys Res Commun, 2007 PubMed Europe PMC
  4. Deng WG, Nishizaki M, Fang B, Roth JA, Ji L; ''Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.''; Biochem Biophys Res Commun, 2007 PubMed Europe PMC
  5. ''AACR Project GENIE: Powering Precision Medicine through an International Consortium.''; Cancer Discov, 2017 PubMed Europe PMC
  6. ''KEGG Non-small cell lung cancer'';,


View all...
105677view22:54, 12 August 2019Khanspersadded drugs
105676view22:28, 12 August 2019Khanspersupdated outcomes
105481view05:38, 8 August 2019KhanspersModified description
105444view04:55, 8 August 2019KhanspersModified description
105192view23:10, 17 July 2019KhanspersModified description
105191view23:09, 17 July 2019Khanspersupdated lit refs
105190view22:42, 17 July 2019Khanspersupdated ERBB2
105189view22:33, 17 July 2019Khanspersadded lit ref
105155view23:21, 12 July 2019Khanspersadded details for retinoic acid signaling and added new interaction type
105154view22:21, 12 July 2019Khanspersupdate FHIT section
105004view04:55, 28 June 2019KhanspersModified description
96916view14:37, 19 April 2018EgonwReplaced secondary ChEBI identifiers with primary identifiers.
96911view04:38, 19 April 2018Khanspersupdated kras
96909view19:34, 18 April 2018Khanspersadded pathway node xrefs
96857view23:28, 14 April 2018AlexanderPicoOntology Term : 'disease pathway' added !
96856view00:06, 14 April 2018KhanspersOntology Term : 'bronchial epithelial cell' added !
96855view00:05, 14 April 2018KhanspersOntology Term : 'lung cancer pathway' added !
96854view00:05, 14 April 2018KhanspersModified description
96853view00:03, 14 April 2018KhanspersModified description
96852view23:58, 13 April 2018KhanspersNew pathway

External references


View all...
NameTypeDatabase referenceComment
AKT1GeneProductENSG00000142208 (Ensembl)
AKT2GeneProductENSG00000105221 (Ensembl)
AKT3GeneProductENSG00000117020 (Ensembl)
ALKGeneProductENSG00000171094 (Ensembl)
ARAFGeneProductENSG00000078061 (Ensembl)
BADGeneProductENSG00000002330 (Ensembl)
BAK1GeneProductENSG00000030110 (Ensembl)
BAXGeneProductENSG00000087088 (Ensembl)
BRAFGeneProductENSG00000157764 (Ensembl)
CASP9GeneProductENSG00000132906 (Ensembl)
CCND1GeneProductENSG00000110092 (Ensembl)
CDK4GeneProductENSG00000135446 (Ensembl)
CDK6GeneProductENSG00000105810 (Ensembl)
CDKN1AGeneProductENSG00000124762 (Ensembl)
CDKN2AGeneProductENSG00000147889 (Ensembl)
Ca2+MetaboliteCHEBI:22984 (ChEBI)
Calcium Signaling PathwayPathway
Cell CyclePathwayWP179 (WikiPathways)
DAGMetaboliteCHEBI:18035 (ChEBI)
DDB2GeneProductENSG00000134574 (Ensembl)
E2F1GeneProductENSG00000101412 (Ensembl)
E2F2GeneProductENSG00000007968 (Ensembl)
E2F3GeneProductENSG00000112242 (Ensembl)
EGFGeneProductENSG00000138798 (Ensembl)
EGFRGeneProductENSG00000146648 (Ensembl)
EML4GeneProductENSG00000143924 (Ensembl)
ERBB2GeneProductENSG00000141736 (Ensembl)
FHITGeneProductENSG00000189283 (Ensembl)
FOXO3GeneProductENSG00000118689 (Ensembl)
GADD45AGeneProductENSG00000116717 (Ensembl)
GADD45BGeneProductENSG00000099860 (Ensembl)
GADD45GGeneProductENSG00000130222 (Ensembl)
GRB2GeneProductGRB2 (HGNC)
HRASGeneProductENSG00000174775 (Ensembl)
IP3MetaboliteCHEBI:16595 (ChEBI)
JAK3GeneProductENSG00000105639 (Ensembl)
KRASGeneProductENSG00000133703 (Ensembl)
MAP2K1GeneProductENSG00000169032 (Ensembl)
MAP2K2GeneProductENSG00000126934 (Ensembl)
MAPK1GeneProductENSG00000100030 (Ensembl)
MAPK3GeneProductENSG00000102882 (Ensembl)
NRASGeneProductENSG00000213281 (Ensembl)
PDK1GeneProductENSG00000152256 (Ensembl)
PI3K-Akt Signaling PathwayPathwayWP4172 (WikiPathways)
PIK3CAGeneProductENSG00000121879 (Ensembl)
PIK3CBGeneProductENSG00000051382 (Ensembl)
PIK3CDGeneProductENSG00000171608 (Ensembl)
PIK3R1GeneProductENSG00000145675 (Ensembl)
PIK3R2GeneProductENSG00000105647 (Ensembl)
PIK3R3GeneProductENSG00000117461 (Ensembl)
PIP3MetaboliteCHEBI:16618 (ChEBI)
PLCG1GeneProductENSG00000124181 (Ensembl)
PLCG2GeneProductENSG00000197943 (Ensembl)
POLKGeneProductENSG00000122008 (Ensembl)
PRKCAGeneProductENSG00000154229 (Ensembl)
PRKCBGeneProductENSG00000166501 (Ensembl)
PRKCGGeneProductENSG00000126583 (Ensembl)
RAF1GeneProductENSG00000132155 (Ensembl)
RARBGeneProductENSG00000077092 (Ensembl)
RASSF1GeneProductENSG00000068028 (Ensembl)
RASSF5GeneProductENSG00000266094 (Ensembl)
RB1GeneProductENSG00000139687 (Ensembl)
RXRAGeneProductENSG00000186350 (Ensembl)
RXRBGeneProductENSG00000204231 (Ensembl)
RXRGGeneProductENSG00000143171 (Ensembl)
Ras Signaling PathwayPathwayWP4223 (WikiPathways)
Retinoic acidMetaboliteCHEBI:6067 (ChEBI)
SOS1GeneProductENSG00000115904 (Ensembl)
SOS2GeneProductENSG00000100485 (Ensembl)
STAT3GeneProductENSG00000168610 (Ensembl)
STAT5AGeneProductENSG00000126561 (Ensembl)
STAT5BGeneProductENSG00000173757 (Ensembl)
STK4GeneProductENSG00000101109 (Ensembl)
TGFAGeneProductENSG00000163235 (Ensembl)
TP53GeneProductENSG00000141510 (Ensembl)
p53 Signaling PathwayPathwayWP707 (WikiPathways)

Annotated Interactions

No annotated interactions

Personal tools